

Appl. No. : 10/761,787  
Filed : January 21, 2004

### REMARKS

The Examiner required restriction to one of six inventions. The Applicants hereby elect without traverse Group I, directed to methods of treating psychosis. Claims 1-9 and new Claims 59-81 encompass the elected invention.

The Examiner also required election of a species from various additional therapeutic agents that may be administered in combination with N-desmethylozapine. The Applicants hereby elect without traverse Aripiprazole as the elected additional therapeutic agent. Claims 1-9 and 60-81 read on this species.

Claim 1 has been amended to recite that the amount of N-desmethylozapine administered is sufficient to increase the level of activity of a muscarinic receptor. Support for this amendment may be found in the specification, for example, in paragraphs 0027 and 0034 and Example 1. Claims 3-8 have been amended to clarify the claim language. New Claims 59-81 have been added. Support for these claims may be found in the specification, for example, in paragraphs 0008, 0011, 0023, 0027, 0029, 0031, 0034, 0040, 0043-0047, and 0055. Non-elected Claims 10-58 have been canceled without prejudice to pursuing them in a divisional, continuation- or continuation-in-part application.

Please charge any fees, including any fees for extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 8-6-07

By: Ryan E. Melnick  
Ryan E. Melnick  
Registration No. 58,621  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550